Recently, checkpoint blockade immunotherapies targeting the programmed cell death‐1/programmed death ligand 1 (PD‐1/PD‐L1) have intensively been studied and provided clinical activity in varieties of malignancies, including NSCLC.5 This evidence concerns the gene CD274 and non-small cell lung carcinoma.